CN Patent

CN101260104A — 抑制磷酸肌醇3-激酶β

Assigned to AstraZeneca AB · Expires 2008-09-10 · 18y expired

What this patent protects

本发明涉及磷酸肌醇(PI)3－激酶β的选择性抑制剂，所述选择性抑制剂在抗血栓形成疗法中的应用，以及通过检测化合物的PI 3－激酶β的选择性抑制活性来筛选可用于新的抗血栓形成疗法的化合物的方法。

USPTO Abstract

本发明涉及磷酸肌醇(PI)3－激酶β的选择性抑制剂，所述选择性抑制剂在抗血栓形成疗法中的应用，以及通过检测化合物的PI 3－激酶β的选择性抑制活性来筛选可用于新的抗血栓形成疗法的化合物的方法。

Drugs covered by this patent

Copiktra (DUVELISIB) · Secura

Patent Metadata

Patent number: CN101260104A
Jurisdiction: CN
Classification: —
Expires: 2008-09-10
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.